Bao Sun1,2, Fazhong He1,2, Yongchao Gao1,2, Jiecan Zhou1,2, Lei Sun3, Rong Liu1,2, Heng Xu4, Xiaoping Chen1,2, Honghao Zhou1,2, Zhaoqian Liu1,2, Wei Zhang5,6. 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 410078, Changsha, People's Republic of China. 2. Hunan Key Laboratory of Pharmacogenetics, Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Central South University, 410078, Changsha, People's Republic of China. 3. Data Analysis Technology Lab, School of Mathematics and Statistics, Henan University, 475004, Kaifeng, People's Republic of China. 4. Department of Laboratory Medicine, National Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. 5. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 410078, Changsha, People's Republic of China. yjsd2003@163.com. 6. Hunan Key Laboratory of Pharmacogenetics, Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Central South University, 410078, Changsha, People's Republic of China. yjsd2003@163.com.
Abstract
PURPOSE: The prognostic impact of visit-to-visit glycemic variability on clinical outcomes in patients with different glycemic control and type 2 diabetes remains obscure. We investigated glucose variability and clinical outcomes for patients in the groups of Good glycemic control (GC), Insufficient glycemic control (IC), and Poor glycemic control (PC) in a prospective cohort study. METHODS: By using data from Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE), 930 patients were enrolled from 61 centers in China and grouped into GC, IC, and PC according to their glycated hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG). Visit-to-visit glycemic variability was defined using the coefficient of variation (CV) of five measurements of HbA1c and FPG taken 3-24 months after treatment. Multivariable Cox proportional hazards models were employed to estimate adjusted hazard ratio (aHR). RESULTS: Among 930 patients in the intensive glucose control, 82, 538, and 310 patients were assigned to GC, IC, and PC, respectively. During the median of 4.8 years of follow-up, 322 patients were observed hypoglycemia and 244 patients experienced major adverse cardiovascular events (MACE). The CV of HbA1c and FPG was significantly lower for GC (6.0 ± 3.8, 11.2 ± 6.2) than IC (8.3 ± 5.6, 17.9 ± 10.6) and PC (9.5 ± 6.3, 19.3 ± 10.8). High glycemic variability was associated with a greater risk of MACE (aHR: 2.21; 95% confidence interval (CI): 1.61-3.03; p < 0.001) and hypoglycemia (aHR: 1.36; 95% CI: 1.04-1.79; p = 0.025) than low glycemic variability in total patients. The consistent trend was also found in subgroups of GC, IC, and PC. CONCLUSIONS: This prospective cohort study showed that glycemic variability was significantly lower for GC than IC and PC. Furthermore, glycemic variability was associated with the risk of MACE and hypoglycemia in total patients and subgroups of different glycemic control.
PURPOSE: The prognostic impact of visit-to-visit glycemic variability on clinical outcomes in patients with different glycemic control and type 2 diabetes remains obscure. We investigated glucose variability and clinical outcomes for patients in the groups of Good glycemic control (GC), Insufficient glycemic control (IC), and Poor glycemic control (PC) in a prospective cohort study. METHODS: By using data from Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE), 930 patients were enrolled from 61 centers in China and grouped into GC, IC, and PC according to their glycated hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG). Visit-to-visit glycemic variability was defined using the coefficient of variation (CV) of five measurements of HbA1c and FPG taken 3-24 months after treatment. Multivariable Cox proportional hazards models were employed to estimate adjusted hazard ratio (aHR). RESULTS: Among 930 patients in the intensive glucose control, 82, 538, and 310 patients were assigned to GC, IC, and PC, respectively. During the median of 4.8 years of follow-up, 322 patients were observed hypoglycemia and 244 patients experienced major adverse cardiovascular events (MACE). The CV of HbA1c and FPG was significantly lower for GC (6.0 ± 3.8, 11.2 ± 6.2) than IC (8.3 ± 5.6, 17.9 ± 10.6) and PC (9.5 ± 6.3, 19.3 ± 10.8). High glycemic variability was associated with a greater risk of MACE (aHR: 2.21; 95% confidence interval (CI): 1.61-3.03; p < 0.001) and hypoglycemia (aHR: 1.36; 95% CI: 1.04-1.79; p = 0.025) than low glycemic variability in total patients. The consistent trend was also found in subgroups of GC, IC, and PC. CONCLUSIONS: This prospective cohort study showed that glycemic variability was significantly lower for GC than IC and PC. Furthermore, glycemic variability was associated with the risk of MACE and hypoglycemia in total patients and subgroups of different glycemic control.
Entities:
Keywords:
Different glycemic control; Hypoglycemia; Major adverse cardiovascular events; Type 2 diabetes; Visit-to-visit glycemic variability
Authors: Yoichiro Hirakawa; Hisatomi Arima; Sophia Zoungas; Toshiharu Ninomiya; Mark Cooper; Pavel Hamet; Giuseppe Mancia; Neil Poulter; Stephen Harrap; Mark Woodward; John Chalmers Journal: Diabetes Care Date: 2014-05-08 Impact factor: 19.112
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Denise E Bonds; Michael E Miller; Richard M Bergenstal; John B Buse; Robert P Byington; Jeff A Cutler; R James Dudl; Faramarz Ismail-Beigi; Angela R Kimel; Byron Hoogwerf; Karen R Horowitz; Peter J Savage; Elizabeth R Seaquist; Debra L Simmons; William I Sivitz; Joann M Speril-Hillen; Mary Ellen Sweeney Journal: BMJ Date: 2010-01-08
Authors: Da Young Lee; Kyungdo Han; Sanghyun Park; Ji Hee Yu; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Yong Gyu Park; Nan Hee Kim Journal: Cardiovasc Diabetol Date: 2020-09-22 Impact factor: 9.951
Authors: Fabian Peeks; Irene J Hoogeveen; R Lude Feldbrugge; Rob Burghard; Foekje de Boer; Marieke J Fokkert-Wilts; Melanie M van der Klauw; Maaike H Oosterveer; Terry G J Derks Journal: J Inherit Metab Dis Date: 2021-05-05 Impact factor: 4.982